{"id":"alk-alutard-5-grasses","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ALK Alutard 5-grasses works by binding to the CD25 antigen, which is a subunit of the IL-2 receptor. This binding prevents IL-2 from binding to its receptor, thereby inhibiting T-cell activation and proliferation. This mechanism is thought to be beneficial in treating various conditions, including allergic diseases.","oneSentence":"ALK Alutard 5-grasses is an immunotherapy that targets the CD25 antigen.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:03.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis"},{"name":"Asthma"}]},"trialDetails":[{"nctId":"NCT04296474","phase":"PHASE1, PHASE2","title":"Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass","status":"COMPLETED","sponsor":"Lars Olaf Cardell","startDate":"2018-05-15","conditions":"Allergic Rhinitis","enrollment":34},{"nctId":"NCT02975479","phase":"PHASE2, PHASE3","title":"Intralymphatic Immunotherapy in Increasing Doses, Substudy","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2016-05","conditions":"Rhinitis, Allergic, Seasonal","enrollment":40},{"nctId":"NCT03394508","phase":"PHASE2, PHASE3","title":"The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2013-01","conditions":"Rhinitis, Asthma, Allergy","enrollment":30},{"nctId":"NCT04210193","phase":"PHASE2, PHASE3","title":"Is Intralymphatic Allergen Immunotherapy Effective and Safe?","status":"COMPLETED","sponsor":"Lars Olaf Cardell","startDate":"2014-04-25","conditions":"Allergic Rhinitis Due to Grass Pollen","enrollment":15},{"nctId":"NCT02679105","phase":"PHASE2, PHASE3","title":"Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-05","conditions":"Rhinitis, Allergic","enrollment":38},{"nctId":"NCT02423707","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2010-08","conditions":"Allergic Rhinitis","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Grass allergen with aluminum adjuvant"],"phase":"phase_2","status":"active","brandName":"ALK Alutard 5-grasses","genericName":"ALK Alutard 5-grasses","companyName":"Lars Olaf Cardell","companyId":"lars-olaf-cardell","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALK Alutard 5-grasses is an immunotherapy that targets the CD25 antigen. Used for Allergic rhinitis, Asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}